LT-α-specific mAb depletes LT-expressing human lymphocytes in Hu-SCID GVHD model.

<p>Spleens were harvested from SCID mice two days following intrasplenic injection of human PBMCs, after one day treatment with anti-LT-α MLTA3698A, anti-LT-α-FcMT or isotype control mAb. <b>A</b>. LT staining on total CFSE-labeled transferred cells and enumeration of percentage of total human cells expressing surface LT. <b>B</b>–<b>D</b>. LT expression and quantitation of mAb treatment effects on specific human lymphocyte populations. Spleen cells were gated on CD4⁺ cells (<b>B</b>), CD8⁺ cells (<b>C</b>) or CD19⁺ cells (<b>D</b>). In each experiment, 2–3 spleens were pooled to provide sufficient cell numbers for data collection. Data show staining for 1 pool out of 3 per experiment, and are representative of a minimum of 2 experiments for each cell type.